People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mustang Bio, Inc. | — | Biotechnology | Series C | $102.3M | $22.7M | 2023 |
Manuel S. Litchman, M.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Manuel S. Litchman, M.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Lindsay A. Rosenwald | 1 | 7 |
| Michael S. Weiss | 1 | 7 |
| Neil A. Herskowitz | 1 | 4 |
| Lindsay A. Rosenwald, M.D. | 1 | 3 |
| Adam J. Chill | 1 | 2 |
| James B. Murphy | 1 | 2 |
| Manuel B. Litchman, M.D. | 1 | 1 |
| Michael J. Zelefsky, M.D. | 1 | 1 |
| Eliot S. Lurier | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.